Profound Medical Corp. appointed Richard R. Fabian as President, effective September 1, 2026, succeeding Mathieu Burtnyk, who transitioned to the newly created role of Chief Technology Officer. Mr. Fabian brings over 29 years of experience in healthcare executive management, most recently serving as CEO of FUJIFILM Sonosite and holding leadership roles at Philips Healthcare. His compensation package includes an annualized base salary of $550,000, a discretionary bonus potential of up to 100% of base salary, a monthly car allowance of $1,000, and a residence lease in Toronto for approximately half his time. He received 200,000 restricted share units vesting over three years and options for 475,000 common shares vesting over four years. Profound Medical Corp. is a commercial-stage medical device company that develops and markets innovative interventional MRI procedures.

Profound Medical Corp. announced the introduction of its new real-time interventional MRI Software, specifically the latest Treatment Delivery Consol (TDC) software, on August 17, 2026. This update is being deployed across the installed base of TULSA-PRO systems to increase procedural efficiency and reduce planning complexity. The company states that physicians report performing up to four procedures per day with current capabilities, while the new software aims to support a roadmap for achieving up to six procedures daily. Profound Medical Corp. operates in the medical device industry, developing and marketing interventional MRI procedures such as TULSA-PRO for prostate ablation and Sonalleve for non-surgical therapy.

Profound Medical Corp. announced on August 14, 2026, that Rashed Dewan resigned as Chief Financial Officer and was replaced by Matthew Sobczyk as Interim CFO. Sobczyk, previously the Corporate Controller since March 2023, will receive an annual base salary of CAD 300,414.58 with a target bonus of 15%. Dewan receives $375,000 in severance and will serve as an independent contractor providing transition services from August 17 through November 25, 2026, at a rate of CAD 200 per hour while retaining vesting on 20,000 restricted share units. Profound Medical Corp. is a commercial-stage medical device company that develops and markets innovative interventional MRI procedures.

Profound Medical Corp. reported financial results for the quarter ended June 30, 2026, recording total revenue of approximately $2.5 million, a 12% year-over-year increase. This figure excludes approximately $3.1 million in TULSA product shipments delayed from late June into July due to logistics issues; excluding this timing difference, revenue would have grown 153%. Gross margin expanded to 78%, and operating expenses declined 16% to $13.0 million, resulting in a net loss of $9.5 million ($0.26 per share), a 39% improvement from the prior year period. The company received over $7.0 million in new purchase orders during the quarter and announced that Johns Hopkins and Prime Healthcare employee health plans now cover the TULSA Procedure. Profound reiterated its full-year 2026 revenue guidance of approximately $25.0 million. Profound Medical Corp. is a commercial-stage medical device company developing and marketing interventional MRI procedures for prostate and other conditions.